CA916798基因在肺癌患者化疗前后肿瘤组织中的表达及其临床意义

段海玲; 梁岚; 邓才霞; 王佳林; 周向东

doi:10.16016/j.1000-5404.201701035

您当前的位置：

首页 >

文章列表页 >

CA916798基因在肺癌患者化疗前后肿瘤组织中的表达及其临床意义

临床医学 | 更新时间：2026-01-09

- CA916798基因在肺癌患者化疗前后肿瘤组织中的表达及其临床意义
- Expression of drug-resistance gene CA916798 before and after chemotherapy for advanced lung cancer and its clinical significance
- 第三军医大学学报 2017年39卷第12期页码：1280-1285
- 作者机构：
  
  400038 重庆，第三军医大学西南医院呼吸内科
- 作者简介：
  
  [周向东，E-mail：xiangdongzhou@126.comZhou Xiangdong, E-mail:xiangdongzhou@126.com
- 基金信息：
- DOI：10.16016/j.1000-5404.201701035
  中图分类号： R394.3;R730.53;R734.2
- 收稿：2017-01-06，
  
  修回：2017-02-09，
  
  纸质出版：2017-06-30
- 稿件说明：
移动端阅览
段海玲, 梁岚, 邓才霞, 等. CA916798基因在肺癌患者化疗前后肿瘤组织中的表达及其临床意义[J]. 第三军医大学学报, 2017,39(12):1280-1285.

Hailing Duan, Lan Liang, Caixia Deng, et al. Expression of drug-resistance gene CA916798 before and after chemotherapy for advanced lung cancer and its clinical significance[J]. Journal of Third Military Medical University, 2017, 39(12): 1280-1285.
段海玲, 梁岚, 邓才霞, 等. CA916798基因在肺癌患者化疗前后肿瘤组织中的表达及其临床意义[J]. 第三军医大学学报, 2017,39(12):1280-1285. DOI： 10.16016/j.1000-5404.201701035.

Hailing Duan, Lan Liang, Caixia Deng, et al. Expression of drug-resistance gene CA916798 before and after chemotherapy for advanced lung cancer and its clinical significance[J]. Journal of Third Military Medical University, 2017, 39(12): 1280-1285. DOI： 10.16016/j.1000-5404.201701035.

摘要

目的

研究耐药基因CA916798在肺癌患者化疗前后肿瘤组织中的表达及意义。

方法

收集2016年3-12月在我院行纤支镜活检、病理确诊的肺癌患者17例，采用实时定量PCR(qRT-PCR)以及免疫组化的方法分析肺癌组织中CA916798基因mRNA及蛋白在化疗前后的表达。

结果

17例肺癌患者经过2个周期规范的前期化疗后，10例患者临床有效(病灶完全缓解或部分缓解)，总体有效率为58.82%。化疗无效组CA916798基因mRNA表达显著高于化疗有效组(

0.05)；前期化疗前，化疗无效组和化疗有效组CA916798蛋白表达阳性率差异无统计学意义；前期化疗后，化疗无效组CA916798蛋白表达阳性率显著高于化疗有效组(

0.05)。前期化疗后病灶稳定的患者中，再次化疗无效者，其CA916798基因表达在前期化疗后显著上调(

0.05)。

结论

肺癌患者肿瘤组织中CA916798基因的表达变化与化疗效果相关，可能成为预测肺癌化疗敏感性的新的参考指标。

Abstract

Objective

To detect the expression of drug-resistant gene CA916798 before and after chemotherapy in patients with advanced lung cancer and explore its clinical significance.

Methods

Between March and December 2016

17 patients with pathologically confirmed advanced lung cancer by fiberoptic bronchoscopy before and after chemotherapy in our department. The biopsy samples of the lung carcinoma tissue collected by bronchoscopy were examined with qRT-PCR and immunohistochemistry for CA916798 expression.

Results

All the 17 patients completed 2 cycles of chemotherapy

and 10 patients showed clinical responses (complete or partial remission) with an overall response rate of 58.82%. The mRNA expression of CA916798 in the tumor was significantly up-regulated in the non-responders than those responding to chemotherapy (

0.05). The positivity rate for CA916798 protein was comparable between the responders and non-responders before chemotherapy (

0.05)

but was significantly higher in the non-responders than in the responders after chemotherapy (

0.05). In the patients with stable disease after primary chemotherapy

the non-responders for secondary chemotherapy presented significantly un-regulated CA916798 expression level after first chemotherapy (

0.05).

Conclusion

The expression of CA916798 is correlated with the effect of chemotherapy and may change after chemotherapy. CA916798 expression level can be used as an indicator for predicting the effect of chemotherapy in patients with advanced lung cancer.

关键词

Keywords

references

Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI:10.3322/caac.21338.

Zhang J, Gold K A, Lin H Y, et al. Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry[J]. J Thorac Oncol, 2015, 10(4): 682-690. DOI: 10.1097/JTO.0000000000000456.

王海晶, 杨和平, 周向东. MDR相关新基因CA916798真核表达载体的构建及其对H446细胞增殖的影响[J].第三军医大学学报, 2007, 29(24): 2315-2318.

Wang H J, Yang H P, Zhou X D. Construction of eukaryotic expression vector of CA916798 and its effect on proliferation of H446 cells[J]. J Third Mil Med Univ, 2007, 29(24): 2315-2318.

Wang H J, Yang H P, Zhou X D, et al. CA916798 regulates multidrug resistance of lung cancer cells[J]. Asian Pac J Cancer Prev, 2011, 12(12): 3403-3408.

Wang Y L, Zhu B J, Qi Z Z, et al. Akt1 enhances CA916798 expression through mTOR pathway[J]. PLoS One, 2013, 8(5): e62327. DOI:10.1371/journal.pone.0062327.

祝冰晶, 王宇亮, 罗虎, 等. CA916798基因通过PI3K/AKT通路参与肺癌顺铂耐药[J].第三军医大学学报, 2013, 35(7): 618-621.

Zhu B J, Wang Y L, Luo H, et al. CA916798 gene is involved in cisplatin resistance in human lung cancer through PI3K/AKT pathway[J]. J Third Mil Med Univ, 2013, 35(7): 618-621.

陈智伟, 廖美琳, 陈玉蓉, 等. WHO标准和RECIST标准评价肺癌化疗疗效的比较[J].循证医学, 2004, 4(2): 83-84, 106. DOI: 10.3969/j.issn.1671-5144.2004.02.011.

Chen Z W, Liao M L, Chen Y R, et al. Measuring response of chemotherapy in lung cancer:WHO versus RECIST criteria[J]. J Evid-Based Med, 2004, 4(2): 83-84, 106. DOI: 10.3969/j.issn.1671-5144.2004.02.011.

于滨, 于慧, 肖菊香, 等. Fz1基因及多药耐药相关基因在肺癌组织中的表达[J].广西医学, 2015, 37(11): 1583-1586. DOI: 10.11675/j.issn.0253-4304.2015.11.16

Yu B, Yu H, Xiao J X, et al. Expression of Fz1 gene and multidrug resistance-related genes in lung cancer tissue[J]. Guangxi Med J, 2015, 37(11): 1583-1586. DOI:10.11675/j.issn.0253-4304.2015.11.16.

Li Y, Ma C, Shi X, et al. Effect of nitric oxide synthase on multiple drug resistance is related to Wnt signaling in non-small cell lung cancer[J]. Oncol Rep, 2014, 32(4): 1703-1708. DOI:10.3892/or.2014.3351.

Amiri-Kordestani L, Basseville A, Kurdziel K, et al. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies[J]. Drug Resist Updat, 2012, 15(1-2): 50-61. DOI:10.1016/j.drup.2012.02.002.

Rocha Gda G, Oliveira R R, Kaplan M A, et al. 3β-Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity[J]. Eur J Pharmacol, 2014, 741: 140-149. DOI: 10.1016/j.ejphar.2014.07.054.

周向东, 刘凌志, 钱桂生, 等.一条新的人肺腺癌耐药相关基因全长cDNA片段的克隆及序列分析[J].癌症, 2002, 21(4): 341-345. DOI: 10.3321/j.issn:1000-467X.2002.04.002

Zhou X D, Liu L Z, Qian G S, et al. Cloning and sequence analysis of a new, full length cDNA fragment of drug resistance related gene in human lung adenocarcinoma[J]. Chin J Cancer, 2002, 21(4): 341-345. DOI: 10.3321/j.issn:1000-467X.2002.04.002.

刘凌志, 钱桂生, 周向东.肺癌耐药相关基因在肺癌组织和肺癌细胞株中的表达[J].癌症, 2003, 22(2): 171-174. DOI:10.3321/j.issn:1000-467X.2003.02.014.

Liu L Z, Qian G S, Zhou X D. Expression of a new lung cancer drug resistance-related gene in lung cancer tissues and lung cancer cell strains[J]. Chin J Cancer, 2003, 22(2): 171-174. DOI:10.3321/j.issn:1000-467X.2003.02.014.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

血栓弹力图评估肺癌患者围手术期凝血状态的临床研究

人肺癌H1299肿瘤干细胞样细胞的分离培养及鉴定

肺癌耐药相关基因CA916798核心启动子区域的初步鉴定

紫杉醇脂质体对比吉西他滨联合顺铂一线治疗中晚期肺鳞癌的疗效评价

赖氨大黄酸通过升高miRNA-451抑制肺癌A549细胞迁移